Stay updated on Neratinib vs Lapatinib in HER2+ Metastatic Breast Cancer Clinical Trial
Sign up to get notified when there's something new on the Neratinib vs Lapatinib in HER2+ Metastatic Breast Cancer Clinical Trial page.
Latest updates to the Neratinib vs Lapatinib in HER2+ Metastatic Breast Cancer Clinical Trial page
- Check3 days agoChange DetectedThe website has updated the 'type of intervention' feature from version v2.13.3 to v2.14.0, indicating a significant revision.SummaryDifference0.3%
- Check10 days agoNo Change Detected
- Check17 days agoNo Change Detected
- Check25 days agoNo Change Detected
- Check32 days agoChange DetectedThe website has been updated from version 2.13.2 to 2.13.3.SummaryDifference0.1%
- Check39 days agoChange DetectedThe website has updated the contact details section for the study, now providing information on who to contact for questions about joining the study and where it is taking place, reflecting a revision from v2.12.2 to v2.13.2.SummaryDifference3%
- Check53 days agoChange DetectedNew features have been added to the website, while several options related to participant groups, interventions, and data download formats have been removed.SummaryDifference4%
- Check61 days agoChange DetectedThe website has been updated to version v2.12.2, introducing new features for downloading data in various formats and allowing users to select specific fields for export.SummaryDifference4%
- Check75 days agoChange DetectedThe website has been updated from version v2.12.0 to v2.12.1.SummaryDifference0.1%
Stay in the know with updates to Neratinib vs Lapatinib in HER2+ Metastatic Breast Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Neratinib vs Lapatinib in HER2+ Metastatic Breast Cancer Clinical Trial page.